Microbubbles (MBs) were observed for the first time in vivo as a curious consequence of
quick saline injection during ultrasound (US) imaging of the aortic root, more than 50 years …

The field of medical ultrasound has undergone a significant evolution since the development
of microbubbles as contrast agents. However, because of their size, microbubbles remain in …

Advancement of ultrasound molecular imaging applications requires not only a reduction in
size of the ultrasound contrast agents (UCAs) but also a significant improvement in the in …

Because of their size (1–10 μm), microbubble-based drug delivery agents suffer from
confinement to the vasculature, limiting tumor penetration and potentially reducing the drug …

Understanding the pressure dependence of the nonlinear behavior of ultrasonically excited
phospholipid-stabilized nanobubbles (NBs) is important for optimizing ultrasound exposure …

Nanobubbles (NBs) have recently garnered widespread attention for their potential use as
dual diagnostic and therapeutic agents. Similar to their micron-sized relatives …

Optimization of contrast-enhanced imaging and focused ultrasound therapy requires a
comprehensive understanding of in vivo microbubble (MB) pharmacokinetics. Prior studies …

Nanoscale ultrasound contrast agents, or nanobubbles, are being explored in preclinical
applications ranging from vascular and cardiac imaging to targeted drug delivery in cancer …

The combination of Ultrasound (US) and US contrast agent (microbubbles, MBs), which is
gas stabilized by a shell such as phospholipids or proteins, has potential as a useful …

Low-intensity ultrasound-triggered sonodynamic therapy (SDT) is a promising noninvasive
therapeutic modality due to its strong tissue penetration ability. In recent years, with the …